Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Viramune, Viramune XR
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other antiretroviral agents to treat HIV-1 infection. It works by binding directly to reverse transcriptase, an enzyme crucial for HIV replication, and inhibiting its RNA-dependent and DNA-dependent DNA polymerase activities. This prevents the virus from converting its RNA into DNA, halting its life cycle and reducing the viral load in the body.
For the treatment of HIV-1 infection in combination with other antiretroviral agents.
Severe and life-threatening skin reactions (Stevens-Johnson Syndrome, toxic epidermal necrolysis) and hepatotoxicity, including fatal hepatic necrosis, have been reported. Nevirapine should not be initiated in patients with moderate to severe hepatic impairment. Discontinue if signs/symptoms of severe skin reaction or hepatitis occur. Use with caution in patients with mild hepatic impairment.
Outcome:
Decreased nevirapine levels
Mechanism:
Induction of CYP3A4
Outcome:
May increase nevirapine levels
Mechanism:
Inhibition of CYP3A4
Outcome:
May decrease nevirapine absorption
Mechanism:
Chelation/altered pH
Most likely new formulation: Long-acting injectable nevirapine (2025, 80% confidence)
Based on increasing prevalence of drug-resistant HIV strains, there is a 70% likelihood of new combination therapies incorporating nevirapine derivatives by 2026.
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Dihydropyridinones